Pulse Biosciences (NASDAQ:PLSE) Stock Passes Above 50 Day Moving Average – Should You Sell?

Pulse Biosciences, Inc (NASDAQ:PLSE)’s share price passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $16.97 and traded as high as $18.61. Pulse Biosciences shares last traded at $17.95, with a volume of 155,500 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on PLSE shares. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, January 22nd. Mizuho set a $30.00 price objective on shares of Pulse Biosciences in a report on Friday, February 6th. Finally, Oppenheimer restated an “outperform” rating and issued a $30.00 target price on shares of Pulse Biosciences in a report on Friday, February 20th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $30.00.

Pulse Biosciences Stock Performance

The firm has a market capitalization of $1.22 billion, a P/E ratio of -16.62 and a beta of 1.74. The firm has a 50 day simple moving average of $16.97 and a two-hundred day simple moving average of $16.25.

Pulse Biosciences (NASDAQ:PLSE) last announced its earnings results on Thursday, February 19th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.06.

Insider Buying and Selling

In other Pulse Biosciences news, insider Kevin Patrick Danahy sold 5,000 shares of Pulse Biosciences stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $23.64, for a total transaction of $118,200.00. Following the transaction, the insider owned 43,298 shares of the company’s stock, valued at $1,023,564.72. This trade represents a 10.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders have sold 85,000 shares of company stock valued at $1,994,400. Company insiders own 74.60% of the company’s stock.

Institutional Trading of Pulse Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Jane Street Group LLC purchased a new position in Pulse Biosciences in the first quarter worth $323,000. AlphaQuest LLC boosted its holdings in shares of Pulse Biosciences by 184.5% in the 2nd quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock worth $134,000 after buying an additional 5,748 shares during the last quarter. Geode Capital Management LLC grew its position in Pulse Biosciences by 7.2% during the second quarter. Geode Capital Management LLC now owns 499,464 shares of the company’s stock valued at $7,538,000 after buying an additional 33,744 shares during the period. Creative Planning increased its holdings in Pulse Biosciences by 26.3% during the second quarter. Creative Planning now owns 18,971 shares of the company’s stock worth $286,000 after buying an additional 3,951 shares during the last quarter. Finally, Swiss National Bank increased its holdings in Pulse Biosciences by 34.9% during the second quarter. Swiss National Bank now owns 32,100 shares of the company’s stock worth $484,000 after buying an additional 8,300 shares during the last quarter. 76.95% of the stock is owned by hedge funds and other institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.